Lexicon Pharmaceuticals, Inc.

LXRX ·Healthcare, Drug Manufacturers - General, United States

Net Cash Flow Breakdown

FY2019 FY2015

Total Cash from Operations: $148.0M

Line Item	Value	% of Total
Capital Expenditures	$0	0.0%
Other Investing	$0	0.0%
Stock Repurchases	$941.0K	0.6%
Other Financing	$661.6K	0.4%
Working Capital	$34.2M	23.1%
Other	$112.2M	75.8%
Net Cash Flow	$0	0.0%